Stock TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Teva Pharmaceutical Industries Limited Stock

Equities

TEVA

US8816242098

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-19 pm EDT 		5-day change 1st Jan Change
12.86 USD +0.63% Intraday chart for Teva Pharmaceutical Industries Limited -3.31% +23.18%
Apr. 19 Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
Apr. 19 Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT

Financials (USD)

Sales 2024 * 15.86B Sales 2025 * 16.35B Capitalization 14.48B
Net income 2024 * 1.54B Net income 2025 * 1.44B EV / Sales 2024 * 1.83 x
Net Debt 2024 * 14.62B Net Debt 2025 * 12.12B EV / Sales 2025 * 1.63 x
P/E ratio 2024 *
10.2 x
P/E ratio 2025 *
9.55 x
Employees 35,737
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.71%
More Fundamentals * Assessed data

Chart Teva Pharmaceutical Industries Limited

Dynamic Chart

Latest news about Teva Pharmaceutical Industries Limited

Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) CI
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis MT
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment DJ
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints MT
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China CI
Teva Pharmaceuticals International, mAbxience Sign Licensing Deal for Oncology Biosimilar Candidate MT
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review MT
Teva Pharmaceutical to Get $150 Million From Carlyle Group's Abingworth for Asthma Therapy With Launch Therapeutics MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11 MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $657,240, According to a Recent SEC Filing MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,048,119, According to a Recent SEC Filing MT
More news

Latest transcript on Teva Pharmaceutical Industries Limited

Logo Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, Q4 2023 Earnings Call, Jan 31, 2024
More transcripts

Analyst Recommendations on Teva Pharmaceutical Industries Limited

JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11 MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12 MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating MT
More recommendations

Press releases Teva Pharmaceutical Industries Limited

Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets AQ
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) BU
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) AQ
Teva Pharmaceutical Industries : Immediate Report PU
Teva Pharmaceutical Industries : Immediate Report PU
More press releases

News in other languages on Teva Pharmaceutical Industries Limited

FDA rechaza aprobación de inyección de Viatris para la esclerosis múltiple
Alcoa : Berkshire Hathaway, Teva... les valeurs à suivre aujourd'hui à Wall Street -
Teva Pharmaceutical Industries : attendu en hausse après l'approbation du Simlandi par la FDA
Après 37 ans à la barre, Nicolas de Tavernost va quitter la direction de M6
Teva Pharmaceutical Industries Limited: costretta a ulteriori cessioni
More news

Quotes and Performance

1 day+0.63%
1 week-3.31%
Current month-8.86%
1 month-3.67%
3 months+15.03%
6 months+57.60%
Current year+23.18%
More quotes

Highs and lows

1 week
12.51
Extreme 12.51
13.57
1 month
12.51
Extreme 12.51
14.47
Current year
10.45
Extreme 10.45
14.47
1 year
7.09
Extreme 7.085
14.47
3 years
6.78
Extreme 6.7791
14.47
5 years
6.07
Extreme 6.07
15.72
10 years
6.07
Extreme 6.07
72.31
More quotes

Managers and Directors - Teva Pharmaceutical Industries Limited

Managers TitleAgeSince
Richard Francis CEO
 Chief Executive Officer 55 22-12-31
Eli Kalif DFI
 Director of Finance/CFO 51 19-12-21
Eric Hughes CTO
 Chief Tech/Sci/R&D Officer - 22-07-31
Members of the board TitleAgeSince
Gerald Lieberman BRD
 Director/Board Member 77 15-08-31
Janet Vergis BRD
 Director/Board Member 60 20-06-08
Sol Barer CHM
 Chairman 76 14-12-31
More insiders

ETFs positioned on Teva Pharmaceutical Industries Limited

Name Weight AuM 1st Jan change Investor Rating
RIZE MEDICAL CANNABIS AND LIFE SCIENCES UCITS ETF ACC - USD ETF Rize Medical Cannabis and Life Sciences UCITS ETF Acc - USD
6.38% 13 M€ -.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
0.27% 18 M€ +1.40% -
More ETFs positioned on Teva Pharmaceutical Industries Limited

Quotes

Date Price Change Volume
24-04-18 12.78 -3.03% 8,957,330
24-04-17 13.18 +0.69% 6,571,690
24-04-16 13.09 -1.06% 8,087,958
24-04-15 13.23 -0.53% 13,512,265
24-04-12 13.3 -4.11% 15,238,796

Delayed Quote Nyse, April 19, 2024 at 04:00 pm EDT

More quotes

Company Profile

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Sector
Pharmaceuticals
Calendar
2024-05-08 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Teva Pharmaceutical Industries Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
12.78 USD
Average target price
15.74 USD
Spread / Average Target
+23.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED Stock Teva Pharmaceutical Industries Limited
+23.18% 14.48B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+24.60% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.63% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 317B
ABBVIE INC. Stock AbbVie Inc.
+7.38% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
NOVARTIS AG Stock Novartis AG
+0.78% 203B
PFIZER, INC. Stock Pfizer, Inc.
-9.69% 144B
AMGEN INC. Stock Amgen Inc.
-6.63% 141B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TEVA Stock